VIRACTA THERAPEUTICS
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
VIRACTA THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Medical Oncology Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Cardiff By The Sea, California, United States
Country:
United States
Website Url:
http://www.viracta.com
Total Employee:
11+
Status:
Active
Contact:
(858)400-8470
Total Funding:
234.9 M USD
Technology used in webpage:
HSTS Linode Ninja Forms SMTP2GO
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Delcath Systems
Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
MEI Pharma
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Olema Oncology
Olema Oncology is a preclinical biotechnology company that develops new drugs for the treatment and prevention of breast cancer.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Advisors List
Board_member
2022-01-01
Board_member
2020-06-01
Board_member
Board_member
2022-08-01
Board_member
Board_member
2021-03-01
Board_member
Current Employees Featured
Mark Rothera President and CEO @ Viracta Therapeutics
President and CEO
2022-09-01
Darrel Cohen Chief Medical Officer @ Viracta Therapeutics
Chief Medical Officer
2023-08-01
Michael Faerm CFO @ Viracta Therapeutics
CFO
2024-05-01
George Stamatoyannopoulos Co-Founder and Director @ Viracta Therapeutics
Co-Founder and Director
Douglas V Faller Scientific Founder; Chair, Scientific Advisory Board @ Viracta Therapeutics
Scientific Founder; Chair, Scientific Advisory Board
2018-01-01
George Hillman COO, VP & Co-Founder @ Viracta Therapeutics
COO, VP & Co-Founder
Dan Chevallard Chief Operating Officer and Chief Financial Officer @ Viracta Therapeutics
Chief Operating Officer and Chief Financial Officer
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-11-30 | Sunesis Pharmaceuticals | Sunesis Pharmaceuticals acquired by Viracta Therapeutics | N/A |
Investors List
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Viracta Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Viracta Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Post-IPO Equity - Viracta Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Viracta Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Viracta Therapeutics
LifeSci Venture Partners
LifeSci Venture Partners investment in Post-IPO Equity - Viracta Therapeutics
aMoon Fund
aMoon Fund investment in Post-IPO Equity - Viracta Therapeutics
Sectoral Asset Management
Sectoral Asset Management investment in Post-IPO Equity - Viracta Therapeutics
Ridgeback Capital
Ridgeback Capital investment in Post-IPO Equity - Viracta Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Viracta Therapeutics
Key Employee Changes
Official Site Inspections
http://www.viracta.com Semrush global rank: 5.56 M Semrush visits lastest month: 1.3 K
- Host name: 209.182.196.37
- IP address: 209.182.196.37
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Viracta Therapeutics"
Home - Viracta Therapeutics, Inc.
Nov 13, 2024 · We are a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Our lead product candidate is Nana …See details»
Leadership - Viracta Therapeutics, Inc.
Our team possesses deep, cross-functional experience and shares a longstanding commitment to developing new medicines to benefit cancer patients. Mark Rothera joined Viracta as …See details»
Company - Viracta Therapeutics, Inc.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you …See details»
Viracta Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The …
View Viracta Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Viracta | Investor Relations - Board of Directors
Dr. Pomerantz has served as a member of the board of directors of Viracta since June 2020 and was appointed Chair in September 2020. Pomerantz served as President, Chief Executive …See details»
Viracta Therapeutics - Crunchbase Company Profile
Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies. Viracta Therapeutics may be growing as indicated by a financial transaction where they provided $8.1 million to XOMA.See details»
Viracta Therapeutics Announces Chief Executive Officer …
Sep 19, 2022 · Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer. Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of Viracta's Board of …See details»
Viracta Therapeutics, Inc. - LinkedIn
Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. We are excited to announce positive data from the Phase...See details»
Viracta Therapeutics Announces Closing of Merger …
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger...See details»
Mark Rothera - Viracta Therapeutics, Inc.
Mark Rothera joined Viracta as President, Chief Executive Officer and Director in September 2022. Mr. Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of commercial and global …See details»
Viracta | Investor Relations - News Releases
SAN DIEGO, November 13, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated …See details»
Viracta Therapeutics Announces Chief Executive Officer Leadership ...
Sep 19, 2022 · Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer. Founding President and CEO Ivor Royston, M.D., will continue to …See details»
Viracta | Investor Relations - Welcome
Nov 13, 2024 · Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is …See details»
Viracta Therapeutics Announces Reprioritization of Resources to …
Nov 6, 2024 · Viracta Therapeutics, Inc. Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten.See details»
Science - Viracta Therapeutics, Inc.
EBV, a member of the γ-herpesvirus family, was the first virus directly implicated in the development of a human tumor and is formally classified as a Group 1 human carcinogen by …See details»
Viracta Therapeutics, Inc. (VIRX) - Yahoo Finance
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.See details»
Viracta Therapeutics Reports Third Quarter 2024 Financial
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus …See details»
Ivor Royston, M.D. - Viracta Therapeutics, Inc.
Ivor Royston, M.D., served as Viracta’s founding President and CEO from 2015 until September 2022. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life …See details»
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
1 day ago · PURPOSETo report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic …See details»
Viracta | Investor Relations - News Releases
Nov 6, 2024 · Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.See details»